Trial Profile
A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Prasterone (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Genelabs Technologies
- 16 Jan 2017 New trial record